Leukemia With IKZF₁ Deletion Benefits From Prolonged Maintenance Therapy
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
MONDAY, July 31, 2023 -- For children with acute lymphoblastic leukemia (ALL), cases with IKZF₁ deletion (IKZF₁del) benefit from prolonged maintenance therapy, according to a study published online July 17 in the Journal of Clinical Oncology.
Noting that IKZF₁del ALL showed poor response to the ALL10 protocol in children in the largest minimal residual disease-defined medium-risk group, accounting for a high number of overall relapses, Rob Pieters, M.D., Ph.D., from the Princess Maxima Center for Pediatric Oncology in Utrecht, Netherlands, and colleagues compared results for the ALL11 protocol, which prolonged therapy for IKZF₁del from two to three years, with the ALL10 protocol. A total of 819 patients with ALL were enrolled in ALL11 and stratified as in ALL10.
The researchers found that in ALL11, the five-year overall survival, event-free survival (EFS), cumulative risk for relapse (CIR), and death in complete remission were 94.2, 89.0, 8.2, and 2.3 percent, respectively. Five-year CIR improved to 10.8 percent from 23.4 percent, and EFS improved to 87.1 percent from 72.3 percent with prolonged maintenance. In a landmark analysis at two years from diagnosis, there was a 2.9-fold reduction of CIR (25.6 to 8.8 percent) and improvement in EFS (74.4 to 91.2 percent). Reduced therapy did not negate the five-year outcomes for ETV6::RUNX₁, Down syndrome, or poor prednisone responders.
"Children with IKZF₁del ALL seem to benefit from a third year of therapy, suggesting to change therapy accordingly for this class of patients," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted July 2023
Read this next
Planetary Health Diet Index Linked to Lower Total, Cause-Specific Mortality
MONDAY, June 10, 2024 -- A higher Planetary Health Diet Index (PHDI) is associated with a lower risk for total and cause-specific mortality, according to a study published online...
Prevalence of Iron Deficiency Varies With Different Definitions
MONDAY, June 10, 2024 -- The prevalence of iron deficiency varies significantly with three different definitions, according to a study published online June 7 in JAMA Network...
AI Blood-Based Lung Cancer Screening Test Developed for Fragmentome
MONDAY, June 10, 2024 -- A novel blood-based lung cancer screening test has been developed and validated using genome-wide sequencing to analyze cell-free DNA (cfDNA)...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.